Cutaneous ulcerations following subcutaneous interferon β injection to a patient with multiple sclerosis

Journal of Dermatology

Volumn 31, Issue 8, 2004, Pages 671-677

  Inafuku, Hisashi ^a   Khan, Mohammed Abul Kasem ^a   Nagata, Tomoko ^a   Nonaka, Shigeo ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Cutaneous ulceration; Interferon beta; Multiple sclerosis

Indexed keywords

IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; STEROID; TOPICAL AGENT;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG INDICATION; FEMALE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; INJECTION SITE; MULTIPLE SCLEROSIS; REVIEW; SKIN ULCER; TREATMENT OUTCOME;

EID: 4544309668     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2004.tb00575.x     Document Type: Review

References (35)

1. Hafler D, Weiner H: MS: A CNS and systemic autoimmune disease, Immunol Today, 10: 104-107, 1989.
2. Raine C: Biology of disease. Analysis of autoimmune demyelination: Its impact upon multiple sclerosis, Lab Invest, 50: 608-635, 1984.
3. Martin R, McFarland HF: Experimental immunotherapies for multiple sclerosis, Springer Semin Immunopathol, 18: 1-24, 1996.
4. Williams KC, Ulvestad E, Mickey WF: Immunology of multiple sclerosis, Clin Neurosci, 2: 229-245, 1994.
5. Gulcher JR, Vartanian T, Stefansson K: Is multiple sclerosis an autoimmune disease?, Clin Neurosci, 2: 246-252, 1994.
6. Scheinberg L, Raine CS: Multiple sclerosis: Experimental and clinical aspects, Ann N Y Acad Sci, 436: 1-518, 1984.
7. IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43: 655-661, 1993.
8. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial, Neurology, 45: 1277-1285, 1995.
9. Jacobs LD, Cookfair DL, Rudick RA, et al: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann Neurol, 39: 285-294, 1996.
10. Rudick R, Jacobs L, Cookfair D, et al: Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis, Neurology, 49: 358-363, 1997.
11. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group: Randomized, double-blind, placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, Lancet, 352: 1498-1504, 1998.
12. European Study Group on Interferon β-1b in Secondary Progressive MS: Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis, Lancet, 352: 1491-1497, 1998.
13. Gaines AR, Varricchio F: Interferon beta-1b injection site reactions and necroses, Multiple Sclerosis, 4: 70-73, 1998.
14. Neilley LK, Goodin DS, Goodkin DE, Hauser SL: Side effect profile of interferon beta-1b in MS: Results of an open label trial, Neurology, 46: 552-554, 1996.
15. Weinberg JM, Wolfe JT, Sood S, Saruk M, Rook AH, Spiers EM: Cutaneous necrosis associated with recombinant interferon injection. Report of 3 cases with interferon β-1b and review of the literature, Acta Derma Venereol, 77: 146-148, 1997.
16. Walther EU, Dang T, Hohlfeld R: Management of side effects of beta-interferon therapy in MS, Int MSJ, 5: 65-70, 1998.
17. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR: Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis, J Am Acad Dermatol, 34: 365-367, 1996.
18. Sheremata WA, Taylor JR, Elgart GW: Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b, N Engl J Med, 332: 1584, 1995.
19. van Rengen AV, Goossens A: Local reactions after subcutaneous injections of β-interferon, Conct Dermatitis, 39: 209, 1997.
20. Feldmann R, Löw-Weiser H, Duschet P, Gschanit F: Necrotizing cutaneous lesions caused by interferon beta injections in patients with multiple sclerosis, Dermatology, 195: 52-53, 1997.
21. Knobler RL, Kelley CL, Trantas F, Lublin FD, Webster GF: β-interferon induced ulcerative skin lesions, J Neuroimmunol, 54: 143, 1994. (abstract)
22. Elgart GW, Sheremata W, Ahn YS: Cutaneous reactions to recombinant human interferon beta-1b: The clinical and histologic spectrum, J Am Acad Dermatol, 37: 553-558, 1997.
23. Cohen BA, Greenberger PA, Saini S: Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b, Allergy and Asthma Proc, 19: 85-88, 1998.
24. Clemens MJ, McNurlan MA: Regulation of cell proliferation and differentiation by interferons, Biochem J, 226: 345-360, 1985.
25. Bogdan C: The function of type 1 interferons in antimicrobial immunity, Curr Opin Immunol, 12: 419-424, 2000.
26. Sheremata WA, Taylor JR, Elgart GW: More on interferon-induced cutaneous necrosis, N Engl J Med, 333: 1223-1224, 1995.
27. Kontochristopoulos G, Stavrinos C, Aroni K, et al: Cutaneous necrosis by subcutaneous injection of α-interferon in a patient with chronic type B hepatitis, J Hepatol, 25: 271, 1996.
28. Oeda E, Shinohara K: Cutaneous necrosis caused by injection of α-interferon in a patient with chronic myelogenous leukemia, Am J Hepatol, 44: 213-214, 1993.
29. Orlow SJ, Friedman-Kien AE: Cutaneous ulcerations secondary to interferon alpha therapy of Kaposi's sarcoma, Arch Dermatol, 128: 566, 1992.
30. Barral-Netto M, Santos S, Santos I, von Sohsten R, Bittencourt AL, Carvalho EM, Barral A, Waters M: Immunochemotherapy with interferon-γ and multidrug therapy for multibacillary leprosy, Acta Tropica, 72: 185-201, 1999.
31. Kolde G, Luger T, Sorg C, Sunderkotter C: Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma, Dermatology, 192: 56-60, 1996.
32. Haas N, Hauptmann S, Paralikoudi D, Muche M, Kolde G: Interferon-gamma treatment induces granulomatous tissue reaction in a case of localized cutaneous leishmaniasis, Am J Dermapathol, 24: 319-323, 2002.
33. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS: A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels, J Rheumatol, 23: 654-658, 1996.
34. Veys EM, Menkes CJ, Emery P: A randomized, double-blind study comparing twenty-four week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis, Arthritis Rheum, 40: 62-68, 1997.
35. Asadullah K, Sterry W, Trefzer U: Cytokine: Interleukin and interferon therapy in dermatology, Clin Exp Dermatol, 27: 578-584, 2002.